

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO. Box 1450 Alexandrin, Vignina 22313-1450 www.uspto.gov

APPLICATION NO.		ILING DATE	CIDOTAL AND DATE OF	3 -		
	 :	ILINO DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/843,150		04/27/2001	Pierre Chambon	065691/0219	7311	
22428	7590	09/09/2003				
FOLEY A	ND LAR	DNFR				
SUITE 500	2.110	DIVER		EXAMI	NER	
3000 K STREET NW			LEFFERS JR, GERALD G			
WASHING?	ron, DC	20007				
				ART UNIT	PAPER NUMBER	
				1636	14	
				DATE MAILED: 09/09/2003	/	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Α	pplication No.	Applicant(s)	
Office Action Summary			9/843,150	CHAMBON, ET AL.	
			xaminer	Art Unit	
		G	erald G Leffers Jr., PhD	1636	
P riod fo	The MAILING DATE of this commu r Reply	nication appear	s on the cover sheet v	with the correspondenc address	
- Exten after S - If the p - If NO - Failure - Any re	DRTENED STATUTORY PERIOD IN AILING DATE OF THIS COMMUNION STATE OF THIS COMMUNION OF THIS PROPERTY OF THIS COMMUNION OF THIS FROM THIS FORM THIS FROM THIS F	IICA HON. s.of 37 CFR 1.136(a) munication. 30) days, a reply with tatutory period will ap	In no event, however, may a in the statutory minimum of thi ply and will expire SIX (6) MO	reply be timely filed rly (30) days will be considered timely. NTHS from the mailing date of this communic	ation.
1)🛛	Responsive to communication(s) for	iled on <u>19 June</u>	2003 .		
2a) <u></u> □	This action is FINAL.		ction is non-final.		
	Since this application is in conditio closed in accordance with the prace on of Claims	n for allowance	except for formal ma	tters, prosecution as to the meri D. 11, 453 O.G. 213.	ts is
4) ⊠ (Claim(s) <u>1-24,26-46 and 49-53</u> is/a	re pending in th	ne application.		
	a) Of the above claim(s) <u>26-46 and</u>			eration	
	Claim(s) is/are allowed.				
6)⊠ (Claim(s) <u>1-24 and 53</u> is/are rejected	•			
7) 🗌 C	Claim(s) is/are objected to.				
8) <u> </u>	Claim(s) are subject to restric	tion and/or ele	ction requirement		
Applicatio	n Papers		and the same of th		
	ne specification is objected to by the				
10)∐ Tr	ne drawing(s) filed on is/are:	a) accepted of	r b)□ objected to by t	ne Examiner.	
	Applicant may not request that any obj	ection to the drav	ving(s) be held in abeya	nce. See 37 CFR 1.85(a).	
11)∐ Th	e proposed drawing correction filed			sapproved by the Examiner.	
	If approved, corrected drawings are rec	uired in reply to	this Office action.		
	e oath or declaration is objected to	by the Examin	er.		
	der 35 U.S.C. §§ 119 and 120				
13) 🗌 A	cknowledgment is made of a claim	for foreign prio	rity under 35 U.S.C. §	119(a)-(d) or (f).	
a) 🗌	All b)☐ Some * c)☐ None of:			•	
1.	Certified copies of the priority of	documents hav	e been received.		
2.	Certified copies of the priority of	locuments have	e been received in Ap	plication No	
·	Copies of the certified copies of application from the Internation the attached detailed Office action	f the priority do	cuments have been i	eceived in this National Stage	
14) <u></u> Ack	nowledgment is made of a claim for	r domestic prio	ity under 35 U.S.C. 8	119(e) (to a provisional applicat	·:\
a)	The translation of the foreign lang nowledgment is made of a claim fo	luage provision	al application has be	en received	.1011)
achment(s)		•			
Notice of	References Cited (PTO-892) Draftsperson's Patent Drawing Review (PT		4) Interview Su	mmary (PTO-413) Paper No(s)	

Art Unit: 1636

DETAILED ACTION

Receipt is acknowledged of an amendment filed 3/3/2003 as Paper No. 10. Receipt is also acknowledged of a supplemental response, filed 6/19/03 as Paper No. 13, in which a corrected version of the marked-up copy of the amended claims was submitted. In Paper No. 10, several claims were amended (claims 1, 5-12, 16 and 17) and a new claim added (claim 53). Claims 1-24, 26-46 and 49-53 are pending in the instant application, with claims 26-46 and 49-52 withdrawn from consideration as being directed to nonelected inventions.

Response to Amendment

Any rejection of record in the previous office action, Paper No. 9 mailed 12/03/02, not addressed herein is withdrawn. This action is not final due to additional new rejections made herein that were not necessitated by applicants' amendment of the claims in Paper No. 10.

Information Disclosure Statement

Receipt is acknowledged of an Information Disclosure Statement filed 3/28/03 as Paper No. 11. The signed and initialed PTO Form 1449 has been mailed along with this action.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

⁽b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Application/Control Number: 09/843,150

Art Unit: 1636

Claims 1, 2, 4, 7, 15-18 are rejected under 35 U.S.C. 102(b) as being anticipated by Wild et al (applicants' submission A6; Gene 1998, Vol. 223, pages 55-66; see the entire document).

This is a new rejection.

Wild et al teach the retrofitting of pre-existing libraries of transposon insertions with FRT and oriV elements in order to use the retrofitted constructs for generation of large quantities of genomic DNA fragments (e.g. the Abstract). In Figure 7, Wild et al demonstrate the generation of isolated DNAs comprising recombination sequences in the order of Lox-FRT-Lox-FRT where the Lox sequences are in opposite orientation with one another and the FRT sequences are in opposite orientation with one another (e.g. Figure 7A). In this example the Lox sequences flank, at least, the first FRT sequence, and the FRT sequences flank the second Lox sequence as well as genomic sequences.

It appears that the Lox-FRT-Lox cassette present in the pMS10.1 and pms10.2 vectors used to generate the recombinant molecules described in Figure 7 comprise additional sequences between the two Lox sites and the FRT site (e.g. see Figure 3; sequences include, at least, oriV, MCS2 and a BamHI restriction site). Therefore, the limitations of claims 2 & 4 have been met.

Because the Office does not have the facilities for examining and comparing the applicant's product with the products of the prior art, the burden is on the applicant to show a novel or unobvious difference between the claimed products and the products of the prior art (e.g. that the products of the prior art do not possess the same material structural and functional characteristics of the claimed product). See in re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977).

Application/Control Number: 09/843,150

Art Unit: 1636

Claim Objections

Claim 13 is objected to because of the following informalities: it is improper to use the term "composed of" delineating the members of a Markush group. It would be remedial to delete the term and replace it with the words "consisting of". Appropriate correction is required.

Claim 15 is objected to because it also comprises improper Markush group language and should be amended to read something like "selected from the group consisting of A, B and C".

Claim 18 is objected to because of the following informalities: the words "are coding for" are grammatically incorrect and should be changed to read "encode".

Claim 23 is objected to because of the following informalities: the word "acaline" is misspelled. Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-24 and 53 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 is vague and indefinite in that the metes and bounds of the phrase "sequences L1 (or L2) are in an orientation opposite to one another" are unclear. It is unclear whether the phrase is meant to encompass embodiments where the to recombination sites are in an orientation where they point to one another, point away from one another, or both. It would be

Art Unit: 1636

remedial to amend the claim language to clearly indicate which of the three possibilities is

encompassed by the cited phrase.

Claim 14 is vague and indefinite in that the claim recites the DNA molecule of claim 1,

but insists that it comprises additional sequences outside of the limits of the DNA molecule of

claim 1. Thus, claim 14 does not further limit claim 1, upon which it is dependent. It would be

remedial to amend the claim to clearly indicate what components of claim 1 are flanked by the

additional SSRTS sites or to write a new claim directed to an isolated nucleic acid comprising

the isolated DNA of claim 1 further flanked by additional SSRTS.

Claim 17 is vague and indefinite in that the metes and bounds of the term "protein of

interest" are unclear. The term is highly subjective and subject to interpretation by the individual

· investigator. It would be remedial to amend the claim language to clearly indicate what is

intended by the words "protein of interest".

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald G Leffers Jr., PhD whose telephone number is (703) 308-

6232. The examiner can normally be reached on 9:30am-6:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached on (703) 305-1998. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is (703) 308-0196.

Gerald G Leffers Jr., PhD

Examiner

Art Unit 1636

Ggl

GERRY LEFFERS

PRIMARY EXAMINER